Cannabis Science, Inc. (CBIS) Announces Broad Patent Licensing Agreement with Endocan Corporation (ENDO) to Develop the Cannabinoid-Based Patent N2010968 'Composition for the Treatment of Neurobehavioral Disorders' for Over-the-Counter, Dispensary, and Fo

COLORADO SPRINGS, Colo., Nov. 21, 2013 /PRNewswire/ -- Cannabis Science, Inc., (NASDAQ OTC: CBIS) a U.S. Company specializing in cannabis formulation-based drug development, announces the signing of a broad licensing agreement with strategic partner Endocan Corporation (NASDAQ OTC: ENDO) to use patent N2010968, entitled "Composition for the Treatment of Neurobehavioral Disorders", for Endocan studies, research and development, and consumer products.

As previously announced, the subject of the patent is development of cannabinoid-based formulations to treat a variety of widespread neurobehavioral conditions, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders. The products that Endocan intends to produce using the patent will target substantial international markets that should prove to help many people in need worldwide. At the same time, Cannabis Science will be moving forward with research and clinical development of pharmaceutical grade drugs via the patent.

"We are very excited with the quick movement in reaching a mutually-beneficial agreement with Endocan Corporation regarding the use of our recently filed patent addressing cannabinoid-based treatment for various neurobehavioral disorders. Both of these companies have different but synergistic missions and can together take this intellectual property to the market at multiple levels," stated Dr. Dorothy Bray, CEO and Director, Cannabis Science, Inc.

Cannabis Science's IP strategy includes developing, owning, and licensing patents for the Company's proprietary drug development operations and collaborations with other industry actors to most effectively help patients.

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.